Robert Daniel Erwin

US Patent:

57030510, Dec 30, 1997

Filed:

Dec 10, 1992

Appl. No.:

7/988739

Inventors:

David L Berliner - Atherton CA
Robert L. Erwin - Vacaville CA
David R. McGee - Vacaville CA

Assignee:

Biosource Technologies, Inc. - Vacaville CA

International Classification:

A61K 3140
A61K 4706
A61K 4746

US Classification:

514 21

Abstract:

The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair. The invention is further useful in protecting a mammal from a toxin-induced disease or from the adverse effects of a toxin by administering an effective amount of the active substance described above.

US Patent:

58176314, Oct 6, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/471071

Inventors:

David L. Berliner - Atherton CA
Robert L. Erwin - Vacaville CA
David R. McGee - Vacaville CA

Assignee:

Biosource Technologies, Inc. - Vacaville CA

International Classification:

A61K 3140
A61K 4706
A61K 4746

US Classification:

514 21

Abstract:

The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair. The invention is further useful in protecting a mammal from a toxin-induced disease or from the adverse effects of a toxin by administering an effective amount of the active substance described above.

US Patent:

52100766, May 11, 1993

Filed:

Nov 5, 1990

Appl. No.:

7/609311

Inventors:

David L. Berliner - Atherton CA
Robert L. Erwin - Vacaville CA
David R. McGee - Vacaville CA

International Classification:

A61K 3700

US Classification:

514 21

Abstract:

The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples. of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair. The invention is further useful in protecting a mammal from a toxin-induced disease or from the adverse effects of a toxin by administering an effective amount of the active substance described above.

US Patent:

49464507, Aug 7, 1990

Filed:

Apr 18, 1989

Appl. No.:

7/341012

Inventors:

Robert L. Erwin - San Francisco CA

Assignee:

Biosource Genetics Corporation - Vacaville CA

International Classification:

A61M 3500
A61F 200

US Classification:

604294

Abstract:

A therapeutic eye shield comprising from about 50% to about 80% collagen and from about 20% to about 50% glucan is disclosed. The collagen acts as a drug delivery system for the therapeutic agent, glucan. The therapeutic eye shields are useful for prophylaxis and treatment of eye infections particularly following ophthalmic surgery or wounding.

US Patent:

57769680, Jul 7, 1998

Filed:

Jun 7, 1995

Appl. No.:

8/488419

Inventors:

David L. Berliner - Atherton CA
Robert L. Erwin - Vacaville CA
David R. McGee - Vacaville CA

Assignee:

Biosource Technologies, Inc. - Vacaville CA

International Classification:

A61K 3140
A61K 3138
A61K 3800

US Classification:

514414

Abstract:

The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair. The invention is further useful in protecting a mammal from a toxin-induced disease or from the adverse effects of a toxin by administering an effective amount of the active substance described above.